Issues
Volume 217 Issue 9
News
News briefs
New hope for pancreatic cancer patients Researchers from the Olivia Newton‐John Cancer Research Institute and the La Trobe University School of Cancer Medicine have found a novel drug target to potentially improve the treatment of pancreatic cancer. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with a low 5‐year survival rate and is associated with poor response to therapy. Elevated expression of the myeloid‐specific haematopoietic cell kinase (HCK) is observed in PDAC and correlates with reduced patient survival. To determine whether aberrant HCK signaling in myeloid cells is involved in PDAC growth and metastasis, the researchers established orthotopic and intrasplenic PDAC tumors in wild‐type and HCK knockout mice. Genetic ablation of HCK impaired PDAC growth and metastasis by inducing an immune‐stimulatory endotype in myeloid cells, which in turn reduced the desmoplastic microenvironment and enhanced cytotoxic effector cell infiltration. Consequently, genetic ablation or therapeutic inhibition of HCK minimised metastatic spread, enhanced the efficacy of chemotherapy, and overcame resistance to anti‐PD1, anti‐CTLA4, and stimulatory anti‐CD40 immunotherapy. The researchers argued their results provided a strong rationale for HCK to be developed as a therapeutic target to improve the response of PDAC to chemo‐ and immunotherapy. The study was published in Cell Reports. “This is important because most pancreatic cancer patients do not respond to existing anti‐cancer drugs, and the survival rate of pancreatic cancer has not improved over the past few decades. We hope to eventually translate these findings into the clinic and improve survival outcomes for pancreatic cancer patients,” lead author Dr Ashleigh Poh said. https://www.cell.com/cell‐reports/fulltext/S2211‐1247(22)01329‐8 Evaluating the worth of early ADHD diagnosis Research from the University of Sydney and Bond University examining quality of life in relation to attention deficit hyperactivity disorder (ADHD) diagnoses suggests a diagnosis in childhood is currently not associated with improved quality of life for Australian teens. The researchers called for a cautious approach to diagnosis by clinicians, particularly for children with mild or borderline hyperactive and inattentive behaviours. The researchers said they were pleased public discussion and new guidelines are creating increased dialogue about ADHD, but felt more research was needed to inform a robust evidence base for diagnosis. The study, which followed 746 children from ages 6–7years to 14–15years from 2006 to 2018, is published in JAMA Network Open. The study followed the children from diagnosis until they were teenagers and self‐reported their perceptions at 14 or 15years of age. The researchers found similar quality of life overall, health, happiness and peer trust. However, those with an ADHD diagnosis reported worse sense of school membership, academic self‐concept and self‐efficacy, more negative social behaviours, and were twice as likely to self‐harm. The researchers suggested that as the study shows youths could potentially be harmed by diagnosis, and interventions to support them may not yet be achieving the desired effects, a cautious clinical approach to ADHD diagnosis in children and adolescents is recommended. In particular, the researchers call for increased and targeted support — within and beyond the medical system — for girls, and for children with high levels of hyperactive and inattentive behaviours, irrespective of whether they are diagnosed. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2797259
Perspectives
The 2022 report of the MJA–Lancet Countdown on health and climate change: Australia unprepared and paying the price
Australia’s transition to renewables and zero carbon remains unacceptably slow
Paul J Beggs · Ying Zhang · Alice McGushin · Stefan Trueck · Martina K Linnenluecke · Hilary Bambrick · Anthony G Capon · Sotiris Vardoulakis · Donna Green · Arunima Malik · Ollie Jay · Maddie Heenan · Ivan C Hanigan · Sharon Friel · Mark Stevenson · Fay H Johnston · Celia McMichael · Fiona Charlson · Alistair J Woodward · Marina B Romanello
A vision of a One Health system for Australia: on the need to rethink our health system
Future threats require an integrated approach to the health of humans, animals and the environment
Sandra G Steele · Jenny‐Ann LML Toribio · Siobhan M Mor
Climate change can be seen through a disaster medicine lens
Our efforts to prepare and respond to the challenges posed by climate change must focus on community support and recovery, providing sustainable financial security and social connectedness
George Braitberg
Climate change, society, and health inequities
Addressing the social determinants and the structural consumptogenic system is critically important if we are to avert a planetary health inequity crisis
Sharon Friel
A planetary health–organ system map to integrate climate change and health content into medical curricula
Health professionals must be prepared to address the health risks and impacts of climate change
Hayden Burch · Laura J Beaton · Grace Simpson · Ben Watson · Janie Maxwell · Kenneth D Winkel
How colleges should lead on climate
If colleges aspire to be leaders in health, they must show leadership on climate
Henry Oakley · Caroline Shaw · Jesse Gale
Medical education
Acute abdominal pain from a zoonosis in Australia
A 70-year-old man presented to the emergency department with abdominal pain, vomiting, diarrhoea and shortness of breath on the background of a one-week history of fevers, dysuria and headaches
Ajinkya Bhonsle · Mithun Nambiar · Michael Swan · Ralph Junckerstorff
Editorials
Health sector leadership is central to the fight against the climate crisis
The health impacts of climate change demand Australia rapidly end its reliance on fossil fuels
Elizabeth Zuccala · Nicholas J Talley
COP27 Climate Change Conference: urgent action needed for Africa and the world
Wealthy nations must step up support for Africa and vulnerable countries in addressing past, present and future impacts of climate change
Lukoye Atwoli · Gregory E Erhabor · Aiah A Gbakima · Abraham Haileamlak · Jean‐Marie Kayembe Ntumba · James Kigera · Laurie Laybourn‐Langton · Bob Mash · Joy Muhia · Fhumulani Mavis Mulaudzi · David Ofori‐Adjei · Friday Okonofua · Arash Rashidian · Maha El‐Adawy · Siaka Sidibé · Abdelmadjid Snouber · James Tumwine · Mohammad Sahar Yassien · Paul Yonga · Lilia Zakhama · Chris Zielinski
The Future Healthy Countdown 2030: holding Australia to account for the health and wellbeing of future generations
It is time to reimagine wellbeing and place the future of our children and young people at the centre of public action
Sandro Demaio · Sharon R Goldfeld · Anne Hollonds · George C Patton · Fiona J Stanley · Rosemary Calder · Kate Lycett · Zuleika Arashiro
Reducing the burden of anaemia for people undergoing major surgery
Pathways and a culture that view blood as disposable must yield to approaches that value patients’ own blood
Philip Crispin
Research
The management of peri‐operative anaemia in patients undergoing major abdominal surgery in Australia and New Zealand: a prospective cohort study
The management of peri-operative anaemia after major abdominal surgery should be standardised to improve patient outcomes
The POSTVenTT Study Collaborative*
Letter
Integration with electronic medication management systems is non‐negotiable for a national allergy/ADR register
To the Editor: We read with interest the article by Drewett and colleagues,1 on anaphylaxis presentations to emergency departments in Victoria, and the linked editorial by Lucas and Vale,2 which proposes a comprehensive adverse drug reaction registry to improve patient safety and care. Re‐exposure of a patient to a medicine to which they have had a previously documented allergy or adverse drug reaction (ADR) is a preventable clinical incident. The Australian sentinel events list includes “medication error resulting in serious harm or death” to ensure public accountability and transparency and drive national improvements in patient safety.3 The availability of accurate and up to date allergy/ADR information for prescribers is vital to support the decision on appropriate treatment and to prescribe a medicine. It is also critical that health professionals who administer medicines and pharmacists who dispense medicines have access to accurate allergy/ADR information, as they provide redundancy within the medication management system to prevent unintentional re‐exposure. We recently undertook an audit to assess the accuracy of medication history documentation performed by pharmacists. Our methodology has been published elsewhere.4 As part of this work, we assessed the quality of pharmacist‐documented allergy/ADR information. Allergy/ADR documentation best practice suggests documentation of the medication name, reaction details and reaction date.5 New findings from our audit identified a total of 108 allergies/ADRs across 99 patients. Of the 52 patients with a previous history of allergy/ADR, only 31% (n = 16) had complete and correct allergy/ADR information documented. These results highlight that the current systems do not adequately support clinicians to provide safe and high quality care. Moreover, these systems risk patient harm through inadvertent re‐exposure to a medicine where there is a previously documented allergy/ADR, given that, at the point of prescribing, administration or dispensing, data are not available, disparate, incorrect or incomplete. We believe the national allergy/ADR registry proposed by Lucas and Vale2 should go one step further, and legislation should mandate interoperability between all electronic prescribing, administration and dispensing systems in Australia. A further challenge will be populating accurate historical allergy/ADR information into the registry. It would require high quality documentation to assist informed clinical decision making. An additional challenge is the complex, hybrid paper and electronic prescribing and documentation systems used across health care settings. Even though these may be challenges to overcome, there are potential opportunities through patient engagement, incentive schemes and machine learning. There needs to be a national consumer‐focused education campaign so the public can be active participants in their own care to support optimal medicine choice based on their allergy/ADR history. We believe a national allergy/ADR registry is of key importance to further enhance patient safety and will be a true system change to overcome the barriers we face in day‐to‐day clinical practice.
Martin L Canning · Andrew Munns · Bonnie Tai
Supplement
Managing mild to moderate COVID-19 in Australia
Med J Aust 2022; 217 (9 Suppl).
Chlamydia prevention and management in Australia: reducing the burden of disease
Stephanie C Munari · Jane L Goller · Margaret E Hellard · Jane S Hocking
Strengthening the reporting of harms of all interventions in clinical trials
Christina Abdel Shaheed · Christopher G Maher · Ann‐Mason Furmage · Tammy Hoffmann · Andrew J McLachlan
Landscape of clinical trials across the pancreatic cancer care continuum: an Australian perspective
Nadia N Khan · Harleen Basrai · Sue M Evans · Liane J Ioannou · Charles HC Pilgrim · John R Zalcberg · Gayle M Jones · Susan Hanson
Twenty‐one years at the Uniting Medically Supervised Injecting Centre, Sydney Australia: addressing the remaining questions
Carolyn A Day · Allison Salmon · Marianne Jauncey · Mark Bartlett · Amanda Roxburgh
Latest evidence casts further doubt on the effectiveness of headspace
Steve Kisely · Jeffrey CL Looi
Robotic surgery: getting the evidence right
Wei Shen Tan · Anthony Ta · John D Kelly